7h
Dealbreaker on MSNRecursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH TumultAltitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered ...
Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...
“Our platforms at Recursion really focused on application of biology, hit discovery, target discovery,” he said. “We've been building that for over a decade and our colleagues at Exscientia ...
Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse ...
Ark Invest chief executive Cathie Wood says the most under-appreciated application of artificial intelligence is “healthcare”. The use of AI in healthcare will contribute significantly to curing ...
Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results